Trailing-twelve-month (TTM) revenue is $17.81 Billion with a year-over-year growth of +3.70%. Revenue represents the total income generated from the company's primary business operations.
Trailing-12-month revenue adds these four fiscal quarters. Amounts are in USD, rounded only to whole currency units.
| Fiscal period | Revenue | Source |
|---|---|---|
| Q3 FY2025Period ended 2025-09-30 | $2,618,000,000 | Filing link unavailableFMP normalized income statementFiling date supplied by FMP: 2025-11-05 |
| Q4 FY2025Period ended 2025-12-31 | $3,910,000,000 | Filing link unavailableFMP normalized income statementFiling date supplied by FMP: 2026-02-12 |
| Q1 FY2026Period ended 2026-03-31 | $4,905,000,000 | Filing link unavailableFMP normalized income statementFiling date supplied by FMP: 2026-05-06 |
| Q2 FY2026Period ended 2026-06-30 | $6,379,000,000 | Filing link unavailableFMP normalized income statementFiling date supplied by FMP: 2026-07-31 |
| TTM revenue | $17,812,000,000 |
Current P/S: $53,860,074,600 market capitalization ÷ $17,812,000,000 TTM revenue = 3.02x.
Market capitalization source: FMP quote. Quote observed 2026-09-18T19:59:59.000Z. Latest revenue period ended 2026-06-30.
Current market capitalization comes from the quote provider. EPS weighted-average shares are a separate measure.
These references are supplied through FMP. Full filing context identifiers and dimensional metadata are unavailable in the normalized feed.
Reported quarterly revenue; no daily interpolation. Q2 FY2026 (2026-06-30): $6.38B.
FMP quote market capitalization / revenue from four consecutive issuer fiscal quarters Quote observation: 2026-09-18T23:00:52.454Z. Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation. Historical series through 2026-09-11.
Selected amounts supplied by FMP for each displayed period. Reviewed label references appear where available; other labels are unverified, and items may overlap.
2025-12-31 · USD
Reviewed labels link to their filing; other labels are unverified FMP source labels.
FMP selected disclosures by reporting period. Rows match exact source labels; they may overlap. N/A means no matching disclosure, not zero. Filing links identify reviewed presentation labels for that period.
| FMP source label (unverified unless linked) | FY20202020-12-31 · USD | FY20212021-12-31 · USD | FY20222022-12-31 · USD | FY20232023-12-31 · USD | FY20242024-12-31 · USD | FY20252025-12-31 · USD |
|---|---|---|---|---|---|---|
| Biologicals | N/A | N/A | N/A | N/A | N/A | $519M |
| Crop Protection | $3.3B | $3.8B |
FMP selected disclosures by reporting period. Rows match exact source labels; they may overlap. N/A means no matching disclosure, not zero. Filing links identify reviewed presentation labels for that period.
| FMP source label (unverified unless linked) | FY20202020-12-31 · USD | FY20212021-12-31 · USD | FY20222022-12-31 · USD | FY20232023-12-31 · USD | FY20242024-12-31 · USD | FY20252025-12-31 · USD |
|---|---|---|---|---|---|---|
| Asia Pacific | $1.4B | $1.5B | $1.5B | $1.4B | $1.3B | $1.3B |
| BRAZIL | N/A | N/A | N/A |
$17.81B
$17.81 Billion
+3.70%
vs. $17.18B a year ago (TTM)
+3.67%
5 Year compound annual growth rate
1 Year
+3.70%
3 Year
+0.53%
5 Year
+3.67%
10 Year
N/A
15 Year
N/A
20 Year
N/A
CAGR shows the annualized growth rate over the specified period, smoothing out year-to-year volatility.
| Year | Revenue | YoY Change | % Change |
|---|---|---|---|
| 2025 | $17.40B | +$493.00M | +2.92% |
| 2024 | $16.91B | ($318.00M) | (1.85%) |
| 2023 | $17.23B | ($229.00M) | (1.31%) |
| 2022 | $17.45B | +$1.80B | +11.50% |
| 2021 | $15.65B | +$1.44B | +10.11% |
| 2020 |
TTM Growth
+3.70%
3-Year CAGR
+0.53%
5-Year CAGR
+3.67%
Revenue growth vs the same fiscal quarter in the prior fiscal year, last 34 comparable quarters.
Current FMP quote-based enterprise value / four-quarter revenue Quote observation: 2026-09-18T23:00:52.454Z. Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation. Historical series through 2026-09-11.
Reviewed presentation labels and parent/child details link to filing evidence; other FMP source labels remain unverified. Mutual exclusivity and reconciliation to a total for the same reporting period and currency have not been verified; percentages and stacked totals are unavailable.
2025-12-31 · USD
Reviewed labels link to their filing; other labels are unverified FMP source labels.
Reviewed presentation labels and parent/child details link to filing evidence; other FMP source labels remain unverified. Mutual exclusivity and reconciliation to a total for the same reporting period and currency have not been verified; percentages and stacked totals are unavailable.
| $4.0B |
| $3.6B |
| $7.5B |
| Fungicides | N/A | N/A | N/A | N/A | N/A | $1.1B |
|---|
| Herbicides | N/A | N/A | N/A | N/A | N/A | $3.7B |
|---|
| Insecticides | N/A | N/A | N/A | N/A | N/A | $1.7B |
|---|
| Other | N/A | N/A | N/A | N/A | N/A | $445M |
|---|
| Seed | $5.2B | $5.6B | $6.0B | $6.4B | $6.5B | $9.9B |
|---|
| N/A |
| $2.9B |
| CANADA | $658M | $754M | $741M | $807M | $794M | $755M |
|---|
| EMEA | $2.8B | $3.1B | $3.3B | $3.4B | $3.1B | $3.1B |
|---|
| Latin America | $2.8B | $3.5B | $4.4B | $3.9B | $3.8B | $3.9B |
|---|
| UNITED STATES | $6.5B | $6.8B | $7.6B | $7.8B | $7.9B | $8.3B |
|---|
| $14.22B |
| +$371.00M |
| +2.68% |
| 2019 | $13.85B | ($441.00M) | (3.09%) |
| 2018 | $14.29B | +$47.00M | +0.33% |
| 2017 | $14.24B | +$199.00M | +1.42% |
